Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 6/20 | 0.36 |
| ▸ | MAOB | P27338 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | SDHA | P31040 | 2/20 | 0.36 |
| ▸ | CALML3 | P27482 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522909 | 1.00 | ACKR3 (0.38) | ACKR3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL3522655 | 0.95 | F10 (0.39) | ACKR3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL3522661 | 0.95 | F10 (0.39) | ACKR3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL3522781 | 0.92 | PKM (0.37) | ACKR3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL3522784 | 0.92 | PKM (0.37) | ACKR3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL3523457 | 0.87 | F10 (0.39) | MAOAMAOBLMNAPTGS1SDHA | |
| SCHEMBL3523454 | 0.87 | F10 (0.39) | MAOAMAOBLMNAPTGS1SDHA | |
| SCHEMBL3519194 | 0.86 | F10 (0.36) | MAOAMAOBLMNAPTGS1SDHA | |
| SCHEMBL3519198 | 0.86 | F10 (0.36) | MAOAMAOBLMNAPTGS1SDHA | |
| SCHEMBL3520796 | 0.85 | F10 (0.35) | MAOAMAOBLMNAPTGS1SDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691889-B2 | Antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-04-06 | — | — | US | claimed |
| US-20050192275-A1 | Novel antimycobacterial compounds | LUPIN LIMITED (IN) | 2005-09-01 | — | — | US | claimed |
| US-7691889-B2 | Antimycobacterial compounds | LUPIN LIMITED (IN) | 2010-04-06 | — | — | US | disclosed |
| US-20050192275-A1 | Novel antimycobacterial compounds | LUPIN LIMITED (IN) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192275-A1 | Novel antimycobacterial compounds | MDH1, IMMT, MLYCD | ACKR3 3724/4885MAOA 2058/4885MAOB 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.